Skip to main content

Liminatus Pharma, Inc.

LIMNW
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001971387

No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $90.1K in total; no superinvestor holds it.

Other share classesLIMN

Q2 2025 vs. Q1 2025

How the institutions holding Liminatus Pharma, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of LIMNW: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders026+26
Shares03.43M+3.43M
Value$0$837.0K+$837.0K

New holders (26)

Institutions that held Liminatus Pharma, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to LIMNW in Q2 2025
InstitutionSharesValue% of portfolio
Cantor Fitzgerald, L. P.875,817$210.1K0.01%
Clear Street LLC805,477$193.2K0.00%
Aristeia Capital LLC313,238$67.3K0.00%
Linden Advisors LP268,199$56.3K0.00%
Saba Capital Management, L.P.233,761$56.1K0.00%
Highbridge Capital Management LLC–$32.5K0.00%
Moore Capital Management, LP125,000$30.4K0.00%
MMCAP International Inc. SPC111,745$26.8K0.00%
Polar Asset Management Partners Inc.122,688$26.4K0.00%
Wolverine Asset Management LLC102,987$24.7K0.00%
Falcon Edge Capital, LP89,098$21.6K0.00%
D. E. Shaw & Co., Inc.83,353$20.2K0.00%
Periscope Capital Inc.50,000$12.0K0.00%
Blue Owl Capital Holdings LP50,000$12.0K0.00%
Toronto Dominion Bank35,200$8.44K0.00%
LMR Partners LLP29,961$7.19K0.00%
Arena Capital Advisors, LLC- CA29,166$7.00K0.01%
Jane Street Group, LLC26,943$6.46K0.00%
Limestone Investment Advisors LP22,562$5.41K0.00%
Cubist Systematic Strategies, LLC15,778$3.79K0.00%
Meteora Capital, LLC15,000$3.60K0.00%
Flow Traders U.S. LLC13,110$3.00K0.00%
DuPont Capital Management Corp6,250$1.52K0.00%
UBS Group AG2,020$4850.00%
HGC Investment Management Inc.1,250$3000.00%
Bank of America Corp300$720.00%

Sold out (0)

Institutions that held Liminatus Pharma, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.

None.